Hepatect Cp

Hepatect Cp is a prescription intravenous immunoglobulin containing Human Hepatitis B Immunoglobulin as the active ingredient. It is supplied in an unspecified strength and dosage form designed for intravenous administration. The product provides passive immunity by delivering antibodies that target hepatitis B virus, helping to prevent infection after exposure. Hepatect Cp is marketed in the European Union and classified as an antiviral (hepatitis B immune globulin).

Hepatect Cp is indicated for the prevention of hepatitis B virus infection in several clinical situations.

- Post‑exposure prophylaxis for individuals with known or suspected exposure to hepatitis B virus. - Prevention of hepatitis B transmission to newborns of mothers who are hepatitis B surface antigen positive. - Supplementation of hepatitis B vaccine in persons with inadequate immune response. - Use in patients undergoing liver transplantation who are at risk for hepatitis B reactivation. - Administration to healthcare workers after occupational needlestick injuries involving hepatitis B‑positive sources.

The safety profile of Hepatect Cp reflects the typical reactions observed with human immunoglobulin products administered intravenously.

Common: - Mild fever or chills during or shortly after infusion. - Headache or dizziness. - Nausea, vomiting, or abdominal discomfort. - Localized pain or erythema at the infusion site.

Serious: - Acute allergic reactions such as urticaria, bronchospasm, or anaphylaxis. - Hemolysis or renal impairment associated with high‑dose immunoglobulin. - Thromboembolic events, including deep‑vein thrombosis or pulmonary embolism.

Before initiating Hepatect Cp, clinicians should evaluate patient history and monitor for conditions that may increase the risk of adverse events.

- Assess for known hypersensitivity to human immunoglobulin or any product component. - Evaluate renal function, especially in patients with pre‑existing kidney disease. - Use caution in individuals with a history of thromboembolic disorders. - Monitor for signs of hemolysis in patients with blood‑group incompatibilities. - Avoid rapid infusion rates; adjust infusion speed based on tolerance. - Consider pregnancy and lactation status, as safety data are limited.

Hepatect Cp may interact with other medications or clinical conditions that affect immune response or blood viscosity.

Avoid: - Concurrent administration of other immunoglobulin products without appropriate spacing. - Use with live vaccines during the same infusion period.

Use with caution: - Anticoagulants or antiplatelet agents, due to potential increased risk of bleeding. - Diuretics, as they may influence renal handling of immunoglobulin. - High‑dose steroids, which can modify immune response and mask infusion reactions. - Cytotoxic chemotherapy, requiring close monitoring for additive immunosuppression.